Pulse Biosciences, Inc. (PLSE) |
| 17.6 -1.65 (-8.57%) 10-10 16:00 |
| Open: | 19.31 |
| High: | 19.35 |
| Low: | 17.45 |
| Volume: | 234,680 |
| Market Cap: | 1,184(M) |
| PE Ratio: | -16.3 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 23.83 |
| Resistance 1: | 20.40 |
| Pivot price: | 18.39 |
| Support 1: | 16.34 |
| Support 2: | 13.83 |
| 52w High: | 25 |
| 52w Low: | 13.766 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Financials
| EPS | -1.080 |
| Book Value | 1.550 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -56.2 |
| Return on Equity (ttm) | -103.5 |
Company news
Fri, 10 Oct 2025
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Fri, 10 Oct 2025
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Fri, 10 Oct 2025
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Fri, 10 Oct 2025
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Tue, 07 Oct 2025
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Tue, 07 Oct 2025
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
